A Phase 1 interventional study of GSK2983559 and Placebo in Inflammatory Bowel Diseases, sponsored by GlaxoSmithKline. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-27.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom — 20 open to participants now, 28 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United Kingdom.
Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, this one is the 56th largest by enrollment of the 70 interventional ones that give a count, is one of 9 that started in 2018, is one of 9 in phase 1, and was the 47th registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →20 of the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United Kingdom
Ages 18–75
GlaxoSmithKline · Sites in United Kingdom
Ages 18–75
Janssen-Cilag Ltd. · Sites in United Kingdom
Ages 18+
Nutricia UK Ltd · Sites in United Kingdom
Ages 3+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 16+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 275 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13 · Phase 3 22 · Phase 4 4
First in 2006; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 68 across 872 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 95 across the 70 interventional studies, 215 across the 42 observational. Of the 67 that completed or were terminated, 26 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 112 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 9 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Inflammatory Bowel Diseases with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT06723418University of GlasgowDevelopment and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS) | 2026-12 |
| NCT06956703University of NottinghamNAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study | 2026-12-31 |
| NCT06877923Nutricia UK LtdElemental 028 Extra Case Studies | 2027-02 |
| NCT06286709University of BirminghamFAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis | 2027-09-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is the first administration of GSK2983559, a selective receptor interacting protein 2 (RIP2) kinase inhibitor, to humans. This will be randomized, double-blinded (sponsor open) and two part study (A and B). Part A of the study is single ascending dose crossover design with two separate cohorts (1 and 2). In Part A, 9 single dose levels will be explored. In Cohort 1, 10 healthy subjects will randomized to receive single oral doses of either GSK2983559 or placebo in a ratio of 4:1 in 5 way cross-over design with 5 treatment periods. In Cohort 2, 8 healthy subjects will be randomized to receive single oral doses of either GSK2983559 or placebo in a ratio of 3:1 in 4 way cross-overs design with 4 treatment periods. In Cohort 2 there will be an additional period (period 5-open label) for assessing GSK2983559 under fed conditions. There will be 48 hours wash-out period between each dose escalation period. Part B is repeat ascending dose sequential group design. It will contain 4 Cohorts of and dosing will be done sequential dosing. Subjects in Part B will receive once daily (QD) dose or twice daily dose (will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A). There will 58 subjects involved in this study. Total duration of Part A will be approximately for 11 Weeks and Part B will be approximately for 15 Weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 will be 5-way crossover with 5 treatment periods. Subjects will be randomized in the ratio 4:1 to receive either single dose of GSK2983559 or placebo.
Drug: GSK2983559 · Drug: Placebo
Cohort 2 will be 4-way crossover design with one additional period of open-label. Subjects will be randomized in the ratio 3:1 to receive either single dose of GSK2983559 or placebo in fasted conditions
Drug: GSK2983559 · Drug: Placebo
In Cohort 2, treatment period 5 will be open-label period. This open-label period is to determine food effect and subjects will receive GSK2983559 under fed conditions.
Drug: GSK2983559
Part B is repeat ascending dose sequential period. There will four cohorts (3-6) of 10 healthy subjects. In each cohort subjects will be randomized to receive GSK2983559 or placebo in ratio 4:1. Subjects will receive GSK2983559 or placebo QD and twice daily dose will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A.
Drug: GSK2983559 · Drug: Placebo
GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
Placebo oral capsules matching GSK2983559 will be available for subjects.
Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement.
Time frame: Up to 7 weeks
Part B: Number of Participants With Non-SAEs and SAEs
An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Non-SAEs and SAEs were planned to be collected.
Time frame: Up to 11 weeks
Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)
Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and white blood cells (WBCs) count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Only those hematology parameters with PCI values have been presented.
Time frame: Up to 7 weeks
Part B: Number of Participants With Worst Case Hematology Parameters of PCI
Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and WBC count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case hematology parameters of PCI were planned to be collected.
Time frame: Up to 11 weeks
Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI
Clinical chemistry parameters included alanine amino transferase (ALT), albumin, alkaline phosphatase (ALP), aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin (T.bil). PCI ranges were: ALT, AST, ALP (high): \>=2\*Upper limit of Normal(ULN) units per liter(U/L), albumin(low): 30 g/L, calcium: \<2(low) or \>2.75 millimoles per liter (mmol/L)(high), creatinine (high): increase from Baseline \>44.2 micromoles per liter(µmol/L), glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and T.bil(high): \>=1.5\*ULN (µmol/L). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Time frame: Up to 7 weeks
Part B: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI
Clinical chemistry parameters included ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were ALT(high): \>=2\*ULN U/L, albumin(low): 30 g/L, alkaline phosphatase(high): \>=2\*ULN U/L, AST(high): \>=2\*ULN U/L, calcium: \<2(low) or \>2.75 mmol/L (high), creatinine (high): increase from Baseline \>44.25 µmol/L, glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and total bilirubin(high): \>=1.5\*ULN (µmol/L). Participants with worst case clinical chemistry parameters of PCI were planned to be collected.
Time frame: Up to 11 weeks
Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method
Urine samples were collected to assess glucose, ketones, occult blood and protein by dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters glucose, ketones, occult blood and protein were categorized as 'any increase from Baseline', which imply any increase in their concentrations in the urine sample. Baseline was defined as latest predose (Day 1) assessment with a non-missing value.
Time frame: Up to 7 weeks
Part B: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method
Urine analysis included assessment of glucose, ketones, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner. Baseline was defined as latest predose (Day 1) assessment with a non-missing value. Participants with worst case any increase in urinalysis results post-Baseline relative to Baseline were planned to be collected.
Time frame: Up to 11 weeks
Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings
12-lead ECGs were obtained using an ECG machine. Only those participants who had any abnormal ECG findings are presented. Abnormal ECG findings were categorized as clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: 1.5, 2, 2.5, 3, 4, 5, 8, 12, 24 and 48 hours post-dose
Part B: Number of Participants With Abnormal ECG Findings
12-lead ECGs were planned to be obtained using an ECG machine. Abnormal ECG findings were categorized as CS and NCS abnormal ECG findings. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Participants with any abnormal ECG findings were planned to be evaluated.
Time frame: Up to 11 weeks
Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI
DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 millimeters of mercury (mmHg) (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Time frame: Up to 7 weeks
Part B: Number of Participants With Worst Case DBP and SBP Values of PCI
DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 mmHg (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case DBP and SBP values of PCI were planned to be evaluated.
Time frame: Up to 11 weeks
Part A: Number of Participants With Worst Case Respiration Rate Values of PCI
Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Time frame: Up to 7 weeks
Part B: Number of Participants With Worst Case Respiration Rate Values of PCI
Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case respiratory rate values of PCI were planned to be evaluated.
Time frame: Up to 11 weeks
Part A: Number of Participants With Worst Case Heart Rate Values of PCI
Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Time frame: Up to 7 weeks
Part B: Number of Participants With Worst Case Heart Rate Values of PCI
Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case heart rate values of PCI were planned to be evaluated.
Time frame: Up to 11 weeks
Part A: Number of Participants With Worst Case Body Temperature Values of PCI
Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Time frame: Up to 7 weeks
Part B: Number of Participants With Worst Case Body Temperature Values of PCI
Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case body temperature values of PCI were planned to be evaluated.
Time frame: Up to 11 weeks
Part A: Number of Participants With Abnormal Findings in Physical Examination
Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. This analysis was not planned and data was not collected and not captured in the database.
Time frame: Up to 7 weeks
Part B: Number of Participants With Abnormal Findings in Physical Examination
Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. Data was not collected and not captured in the database.
Time frame: Up to 11 weeks
Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points
Blood samples were collected to evaluate activated partial thromboplastin time (APTT) and prothrombin time (PT) at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1, Pre-dose), 24 and 48 hours post-dose
Part B: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points
Blood samples were planned to be collected to evaluate PTT and PT at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and Up to 11 weeks
Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points
Blood samples were collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1, Pre-dose), 24 and 48 hours
Part B: Change From Baseline in International Normalized Ratio at Indicated Time Points
Blood samples were planned to be collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and Up to 11 weeks
Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559
Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): AUC(0-t) for GSK2983559
Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): AUC(0-inf) for GSK2983559
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): Cmax for GSK2983559
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559
Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): T1/2 for GSK2983559
Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559
Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): Tmax for GSK2983559
Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559)
Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: AUC(0-t) for GSK2983559 Following Single Dose on Day 1
Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: AUC(0-t) for GSK2983559 on Day 14
Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1
Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) on Day 14
Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: AUC From 0 Hours to the Time of Next Dosing AUC(0-tau) for GSK2983559 Following Single Dose on Day 1
Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: AUC(0-tau) for GSK2983559 on Day 14
Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: AUC(0-tau) for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1
Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: AUC(0-tau) for GSK2668176 (Active Moiety of GSK2983559) on Day 14
Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: Cmax for GSK2983559 Following Single Dose on Day 1
Blood samples were planned to be collected to measure Cmax at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: Cmax for GSK2983559 on Day 14
Blood samples were planned to be collected to measure Cmax at indicated time-points.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: Cmax for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1
Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: Cmax for GSK2668176 (Active Moiety of GSK2983559) on Day 14
Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: Tmax for GSK2983559 Following Single Dose on Day 1
Blood samples were planned to be collected to measure Tmax at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: Tmax for GSK2983559 on Day 14
Blood samples were planned to be collected to measure Tmax at indicated time-points.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: Tmax for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1
Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: Tmax for GSK2668176 (Active Moiety of GSK2983559) on Day 14
Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: T1/2 for GSK2983559 Following Single Dose on Day 1
Blood samples were planned to be collected to measure T1/2 at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: T1/2 for GSK2983559 on Day 14
Blood samples were planned to be collected to measure T1/2 at indicated time-points.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: T1/2 for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1
Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period
Part B: T1/2 for GSK2668176 (Active Moiety of GSK2983559) on Day 14
Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: Accumulation Ratio of GSK2983559
Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part B: Accumulation Ratio of GSK2668176 (Active Moiety of GSK2983559)
Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period
Part A (Cohort 2): AUC (0-t) for GSK2983559 in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): AUC(0-t) for GSK2983559 in Fed Condition (Period 5)
Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)
Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
Part A (Cohort 2): AUC(0-inf) for GSK2983559 in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): AUC(0-inf) for GSK2983559 in Fed Condition (Period 5)
Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)
Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
Part A (Cohort 2): Cmax for GSK2983559 in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): Cmax for GSK2983559 in Fed Condition (Period 5)
Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)
Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
Part A (Cohort 2): Tmax for GSK2983559 in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): Tmax for GSK2983559 in Fed Condition (Period 5)
Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)
Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
Part A (Cohort 2): T1/2 for GSK2983559 in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): T1/2 for GSK2983559 in Fed Condition (Period 5)
Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)
Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4
Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)
Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5
This was a 2-part study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2983559 in healthy participants. The study was terminated early due to non-clinical toxicology findings and reduced safety margins. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
| Milestone | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 6 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 3 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Milestone | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 6 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 6 | 0 | 0 |
| Withdrew: Study closed/terminated | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 6 | 0 | 0 |
| Milestone | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement.
| Participants | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| Non-SAEs | 6 | 2 | 2 | 1 | 1 | 2 | 4 | 4 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Non-SAEs and SAEs were planned to be collected.
No measurements were reported for this outcome.
Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and white blood cells (WBCs) count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Only those hematology parameters with PCI values have been presented.
| Participants | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| Hematocrit, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Hematocrit, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Hemoglobin, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes, To low | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes, To within range or no change | 15 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Lymphocytes, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet count, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Platelet count, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Neutrophils, To low | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Total Neutrophils, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 8 | 9 |
| Total Neutrophils, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC count, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC count, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| WBC count, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and WBC count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case hematology parameters of PCI were planned to be collected.
No measurements were reported for this outcome.
Clinical chemistry parameters included alanine amino transferase (ALT), albumin, alkaline phosphatase (ALP), aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin (T.bil). PCI ranges were: ALT, AST, ALP (high): \>=2\*Upper limit of Normal(ULN) units per liter(U/L), albumin(low): 30 g/L, calcium: \<2(low) or \>2.75 millimoles per liter (mmol/L)(high), creatinine (high): increase from Baseline \>44.2 micromoles per liter(µmol/L), glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and T.bil(high): \>=1.5\*ULN (µmol/L). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
| Participants | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| ALT, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| ALT, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Albumin, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| ALP, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, To within range or no change | 15 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| AST, To high | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Calcium, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Creatinine, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Glucose, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Potassium, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Sodium, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| T.bil, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| T.bil, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| T.bil, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical chemistry parameters included ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were ALT(high): \>=2\*ULN U/L, albumin(low): 30 g/L, alkaline phosphatase(high): \>=2\*ULN U/L, AST(high): \>=2\*ULN U/L, calcium: \<2(low) or \>2.75 mmol/L (high), creatinine (high): increase from Baseline \>44.25 µmol/L, glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and total bilirubin(high): \>=1.5\*ULN (µmol/L). Participants with worst case clinical chemistry parameters of PCI were planned to be collected.
No measurements were reported for this outcome.
Urine samples were collected to assess glucose, ketones, occult blood and protein by dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters glucose, ketones, occult blood and protein were categorized as 'any increase from Baseline', which imply any increase in their concentrations in the urine sample. Baseline was defined as latest predose (Day 1) assessment with a non-missing value.
| Participants | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Urine analysis included assessment of glucose, ketones, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner. Baseline was defined as latest predose (Day 1) assessment with a non-missing value. Participants with worst case any increase in urinalysis results post-Baseline relative to Baseline were planned to be collected.
No measurements were reported for this outcome.
12-lead ECGs were obtained using an ECG machine. Only those participants who had any abnormal ECG findings are presented. Abnormal ECG findings were categorized as clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,9 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal NCS, 3 hours, n=6,0,0,0,0,0,9,9 | 0 | — | — | — | — | — | 1 | 0 |
| Abnormal CS, 3 hours, n=6,0,0,0,0,0,9,9 | 0 | — | — | — | — | — | 0 | 0 |
| Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal NCS, 5 hours, n=6,0,0,0,0,0,9,9 | 0 | — | — | — | — | — | 0 | 2 |
| Abnormal CS, 5 hours, n=6,0,0,0,0,0,9,9 | 0 | — | — | — | — | — | 0 | 0 |
| Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 |
| Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
12-lead ECGs were planned to be obtained using an ECG machine. Abnormal ECG findings were categorized as CS and NCS abnormal ECG findings. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Participants with any abnormal ECG findings were planned to be evaluated.
No measurements were reported for this outcome.
DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 millimeters of mercury (mmHg) (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
| Participants | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| DBP, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBP, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| DBP, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP, To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP, To within range or no change | 16 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| SBP, To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 mmHg (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case DBP and SBP values of PCI were planned to be evaluated.
No measurements were reported for this outcome.
Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
| Participants | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| To low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| To within range or no change | 12 | 7 | 6 | 8 | 7 | 7 | 7 | 8 |
| To high | 4 | 1 | 2 | 0 | 1 | 1 | 2 | 1 |
Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case respiratory rate values of PCI were planned to be evaluated.
No measurements were reported for this outcome.
Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
| Participants | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| To low | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| To within range or no change | 16 | 8 | 8 | 8 | 8 | 7 | 8 | 9 |
| To high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case heart rate values of PCI were planned to be evaluated.
No measurements were reported for this outcome.
Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
| Participants | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| To low | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 2 |
| To within range or no change | 15 | 8 | 7 | 8 | 8 | 6 | 8 | 7 |
| To high | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case body temperature values of PCI were planned to be evaluated.
No measurements were reported for this outcome.
Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. This analysis was not planned and data was not collected and not captured in the database.
No measurements were reported for this outcome.
Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. Data was not collected and not captured in the database.
No measurements were reported for this outcome.
Blood samples were collected to evaluate activated partial thromboplastin time (APTT) and prothrombin time (PT) at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Seconds | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| APTT, 24 hours, n=16,8,8,7,8,8,9,9 | 0.4 ± 3.35 | 0.8 ± 1.83 | 2.9 ± 2.85 | -0.7 ± 1.80 | 1.0 ± 1.77 | 1.0 ± 2.56 | -1.3 ± 6.10 | -1.2 ± 2.11 |
| APTT, 48 hours, n=16,8,8,8,8,8,8,9 | 0.5 ± 2.99 | -0.3 ± 2.66 | 0.5 ± 3.07 | 0.8 ± 2.38 | 0.0 ± 1.69 | 2.3 ± 2.71 | -3.0 ± 6.37 | -2.4 ± 2.96 |
| PT, 24 hours, n=16,8,8,7,8,8,9,9 | 0.1 ± 0.62 | 0.3 ± 0.46 | -0.3 ± 0.46 | 0.1 ± 0.69 | -0.1 ± 0.35 | 0.1 ± 0.35 | -0.2 ± 1.48 | 0.0 ± 0.87 |
| PT, 48 hours, n=16,8,8,8,8,8,8,9 | -0.1 ± 0.34 | 0.0 ± 0.53 | -0.3 ± 0.46 | 0.1 ± 0.64 | -0.1 ± 0.35 | 0.1 ± 0.35 | -0.4 ± 1.51 | 0.1 ± 0.93 |
Blood samples were planned to be collected to evaluate PTT and PT at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
No measurements were reported for this outcome.
Blood samples were collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Ratio | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| 24 hours, n=16,8,8,7,8,8,9,9 | 0.001 ± 0.0496 | 0.010 ± 0.0278 | -0.005 ± 0.0404 | -0.019 ± 0.0430 | -0.002 ± 0.0282 | 0.017 ± 0.0354 | -0.028 ± 0.1204 | -0.019 ± 0.0752 |
| 48 hours, n=16,8,8,8,8,8,8,9 | -0.018 ± 0.0248 | 0.013 ± 0.0345 | -0.021 ± 0.0356 | -0.009 ± 0.0405 | -0.024 ± 0.0233 | 0.020 ± 0.0293 | -0.035 ± 0.1165 | -0.020 ± 0.0738 |
Blood samples were planned to be collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
No measurements were reported for this outcome.
Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Hours*nanogram per milliliter | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559 | NA ± NA | NA ± NA | NA ± NA | 1.4088 ± 38.9 | 7.2488 ± 63.5 |
Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Hours*nanogram per milliliter | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): AUC(0-t) for GSK2983559 | 8.1765 ± 61.7 | 5.9980 ± 67.3 |
Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Hours*nanogram per milliliter | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) | 96.7389 ± 19.3 | 250.6231 ± 36.3 | 390.3911 ± 17.5 | 889.6956 ± 17.2 | 2760.8122 ± 41.3 |
Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Hours*nanogram per milliliter | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) | 2608.4326 ± 59.7 | 2857.1378 ± 39.9 |
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Hours*nanogram per milliliter | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Hours*nanogram per milliliter | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): AUC(0-inf) for GSK2983559 | NA ± NA | NA ± NA |
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Hours*nanogram per milliliter | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) | 104.28 ± 19.4 | 257.28 ± 36.0 | 405.39 ± 16.0 | 911.53 ± 17.1 | 2860.23 ± 43.0 |
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Hours*nanogram per milliliter | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) | 2717.46 ± 57.5 | 2950.11 ± 38.5 |
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Nanograms per milliliter | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559 | NA ± NA | NA ± NA | 0.2291 ± 12.4 | 0.4034 ± 37.3 | 1.1937 ± 40.2 |
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Nanograms per milliliter | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): Cmax for GSK2983559 | 1.3931 ± 69.3 | 1.1244 ± 70.0 |
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Nanograms per milliliter | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559) | 10.4980 ± 34.5 | 25.9587 ± 38.6 | 38.4341 ± 35.5 | 93.8714 ± 19.5 | 305.9839 ± 33.0 |
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Nanograms per milliliter | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) | 314.2321 ± 113.3 | 351.0316 ± 68.9 |
Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Hours | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Hours | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): T1/2 for GSK2983559 | NA ± NA | NA ± NA |
Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Hours | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559) | 7.044 ± 33.2 | 8.304 ± 26.9 | 9.649 ± 26.9 | 8.717 ± 23.0 | 9.799 ± 24.7 |
Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Hours | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) | 10.480 ± 20.4 | 9.526 ± 25.6 |
Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Hours | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559 | NA (NA to NA) | NA (NA to NA) | 4.500 (4.00 to 5.00) | 4.005 (3.00 to 5.01) | 4.000 (3.00 to 4.00) |
Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
| Hours | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): Tmax for GSK2983559 | 3.506 (3.00 to 6.00) | 4.000 (3.00 to 5.00) |
Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Hours | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg |
|---|---|---|---|---|---|
| Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559) | 3.000 (1.51 to 4.00) | 2.758 (2.00 to 4.00) | 4.006 (2.50 to 5.98) | 4.037 (2.00 to 5.01) | 3.000 (2.00 to 4.00) |
Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
| Hours | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|
| Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) | 3.083 (2.00 to 4.00) | 3.500 (2.00 to 6.00) |
Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Cmax at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Cmax at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Tmax at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Tmax at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure T1/2 at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure T1/2 at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
No measurements were reported for this outcome.
Collected over Non-SAEs and SAEs were reported from start of study treatment (Day 1) up to Week 7 for Part A. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Part A-Cohort 1: GSK2983559 2 mg | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Part A-Cohort 1: GSK2983559 4 mg | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Part A-Cohort 1: GSK2983559 10 mg | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part A-Cohort 1: GSK2983559 30 mg | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part A-Cohort 1: GSK2983559 100 mg | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Part A-Cohort 2: GSK2983559 200 mg | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Part A-Cohort 2: GSK2983559 400 mg | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Event | Part A: Placebo | Part A-Cohort 1: GSK2983559 2 mg | Part A-Cohort 1: GSK2983559 4 mg | Part A-Cohort 1: GSK2983559 10 mg | Part A-Cohort 1: GSK2983559 30 mg | Part A-Cohort 1: GSK2983559 100 mg | Part A-Cohort 2: GSK2983559 200 mg | Part A-Cohort 2: GSK2983559 400 mg |
|---|---|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 0/16 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/9 | 2/9 |
| NasopharyngitisInfections and infestations | 0/16 | 1/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/9 | 1/9 |
| Tooth abscessInfections and infestations | 0/16 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/9 | 0/9 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/16 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/9 | 0/9 |
| Respiratory tract irritationRespiratory, thoracic and mediastinal disorders | 0/16 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/9 | 0/9 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/16 | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/9 | 0/9 |
| Influenza like illnessGeneral disorders | 2/16 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/9 | 0/9 |
| Catheter site erythemaGeneral disorders | 0/16 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/9 | 0/9 |
| Vessel puncture site painGeneral disorders | 0/16 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/9 | 0/9 |
| Arthropod biteInjury, poisoning and procedural complications | 0/16 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 | 0/9 | 1/9 |
Only data for Part A is presented as study was terminated during Part A and hence Part B was not initiated.
| Age, Continuous(Years) | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/ Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 38.0 ± 11.31 | 46.0 ± 14.14 | 52.7 ± 11.85 | 45.5 ± 13.44 | 59.3 ± 4.73 | 42.3 ± 10.50 | 33.8 ± 7.04 | 42.8 ± 11.89 | — | — | 44.2 ± 11.73 |
| Sex: Female, Male(Participants) | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/ Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 2 | 2 | 3 | 2 | 3 | 6 | 4 | 9 | 0 | 0 | 31 |
| Race/Ethnicity, Customized(Participants) | Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg | Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo | Part A-Cohort 2: Placebo/GSK 400mg | Part A-Cohort 2: GSK 200mg/ Placebo | Part A-Cohort 2: GSK 200mg/GSK 400mg | Part B: Placebo | Part B: GSK2983559 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian - Central/South Asian Heritage | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 3 |
| White - White/Caucasian/European Heritage | 2 | 2 | 3 | 1 | 3 | 5 | 2 | 9 | 0 | 0 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jan 2018 to primary completion in Feb 2019, 13 months.
Results were first posted in Jun 2020, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.